Birdshot retinopathy, more formally called birdshot chorioretinopathy or birdshot retinochoroiditis, is a rare chronic inflammatory eye disease that attacks the choroid and retina at the back of both eyes. It gets its name from the scatter-pattern of pale, cream-colored spots across the fundus that resemble birdshot pellet spray. The condition almost exclusively affects middle-aged people of European descent and has one of the strongest known associations between a disease and a single genetic marker, an immune-system molecule called HLA-A29. Because it is rare and its early symptoms are easy to dismiss, many people go months or years before getting an accurate diagnosis.
Who Gets Birdshot Retinopathy
Birdshot retinopathy is overwhelmingly a disease of people with European ancestry, typically appearing between the ages of 40 and 60. Women are affected more than men. A large UK-based study found a median age at diagnosis of 46 and reported that women made up 78% of patients.1Eye. The incidence, presenting clinical findings and treatment patterns of Birdshot Retinochoroiditis in a high-prevalence region: findings from Northern Ireland, England and Wales A French cohort with longer follow-up found a female-to-male ratio of about 1.6 to 1 and an average disease duration stretching close to ten years.2PubMed. Birdshot Retinochoroidopathy: Prognostic Factors of Long-term Visual Outcome The condition is vanishingly rare in people of Asian or African descent, which tracks with the genetic driver discussed below.
Exact incidence numbers are hard to pin down for any rare disease, and birdshot is no exception. It accounts for a small fraction of all uveitis referrals in Western countries, and many specialists see only a handful of new cases a year. Delayed diagnosis remains a significant problem. Patients often encounter several eye-care providers before the characteristic spots are recognized and the correct workup is ordered.3PubMed Central. Birdshot Chorioretinopathy: A Review
The HLA-A29 Connection
Nearly every patient with confirmed birdshot retinopathy carries the HLA-A29 gene. In one well-known series of 49 patients, roughly 96% were HLA-A29 positive.4American Journal of Ophthalmology. HLA-A29 and Birdshot Chorioretinopathy That makes HLA-A29 testing an almost indispensable part of diagnosis: a negative result in a Caucasian patient should make you seriously reconsider whether the condition really is birdshot.
HLA-A29 is a cell-surface protein that helps the immune system distinguish self from non-self. Carrying it does not guarantee you will develop birdshot. Roughly 7% of people of European descent carry HLA-A29, and the overwhelming majority never develop any eye disease. Something else, still not fully understood, has to go wrong for the immune system to turn on the eye’s own tissue. What the HLA-A29 link tells researchers is that the disease involves a misdirected immune response where the body’s T cells attack cells in the choroid and retina as if they were foreign invaders.
Intriguingly, the specific subtype matters. HLA-A*2902 is the most common variant in Caucasians and in birdshot patients. A handful of Caucasian patients have carried the HLA-A*2901 variant instead, but the disease remains absent or extremely rare in Asia, where HLA-A*2901 rather than *2902 is the predominant subtype.5PubMed. Birdshot chorioretinopathy That geographic split is part of why birdshot is essentially confined to people with European heritage.
What Drives the Inflammation
The immune process behind birdshot involves T cells, particularly subsets that produce inflammatory signaling molecules. Studies analyzing fluid from the front chamber of affected eyes have found elevated levels of several pro-inflammatory molecules, including interleukin-17, interleukin-6, and tumor necrosis factor alpha (TNF-α). These levels were significantly higher inside the eye than in the patient’s own blood, pointing to a localized inflammatory process rather than a body-wide one.6American Journal of Ophthalmology. Intraocular Interleukin-17 and Proinflammatory Cytokines in HLA-A29–Associated Birdshot Chorioretinopathy A systematic review of immune mediators in birdshot confirmed that elevated intraocular IL-6, TNF, and several chemokines consistently point to localized inflammation.7PubMed. Immune Mediators in Birdshot Chorioretinopathy: A Systematic Review
Blood-based studies of patients with active disease have also found a tendency toward higher proportions of certain inflammatory T cell populations compared to healthy controls.8Scientific Reports. Analysis of peripheral inflammatory T cell subsets and their effector function in patients with Birdshot Retinochoroiditis The clinical takeaway is that birdshot is an autoimmune or auto-inflammatory condition, and its treatment centers on reining in that immune attack.
Symptoms and How They Progress
Birdshot retinopathy typically presents with blurred vision, floaters, and a feeling that something is “off” with sight, especially in dim light. Patients often report photopsias (flashing lights), blind spots near the center of vision, and nyctalopia, which is difficulty seeing in low-light conditions.9PubMed Central. Birdshot retinochoroidopathy Because these complaints are vague and overlap with many other conditions, early birdshot is frequently misdiagnosed as garden-variety floaters, age-related changes, or even anxiety.
The loss of night vision and color perception can be among the earliest and most distressing symptoms. Some patients describe it as losing the richness of colors before their acuity drops. Over time, without treatment, the inflammation damages photoreceptors, thins the retina, and erodes the visual field. The disease is bilateral, meaning both eyes are affected, though one may be worse than the other at any given moment.
The course is chronic and relapsing. Inflammation can flare and quiet down unpredictably, and patients often feel the effects of the disease even between obvious flares. That slow, smoldering quality is what makes ongoing monitoring so important.
How It Is Diagnosed
Diagnosis rests on three legs: the clinical appearance of scattered cream-colored spots in the back of the eye, a positive HLA-A29 test, and imaging that confirms the pattern and rules out mimics. No single test clinches the diagnosis alone; the combination is what makes the case.
Color fundus photography captures the classic birdshot lesions. Fluorescein angiography (FFA) reveals vascular leakage from inflamed retinal vessels. Indocyanine green angiography (ICGA) is particularly useful because it visualizes the deeper choroidal layer, which is where many birdshot lesions live and where FFA alone may miss them. A consensus task force identified color fundus photography, FFA, and ICGA as the key imaging modalities for initial diagnosis, with ICGA singled out for its ability to detect choroidal lesions.10PubMed. Evidence and Consensus-based Imaging Guidelines in Birdshot Chorioretinopathy: Multimodal Imaging in Uveitis (MUV) Taskforce Report 8
Optical coherence tomography (OCT) adds another layer. While not essential for establishing the initial diagnosis, OCT excels at catching complications like cystoid macular edema (fluid-filled pockets in the central retina) and retinal thinning, both of which threaten central vision.11PubMed. Evidence and Consensus-based Imaging Guidelines in Birdshot Chorioretinopathy: Multimodal Imaging in Uveitis (MUV) Taskforce Report 8 Newer technologies such as OCT angiography are also being studied for their ability to track microvascular changes without injecting dye.12PubMed. Multimodal Imaging in Birdshot Retinochoroiditis
Electroretinography as a Monitoring Tool
One of the trickiest things about birdshot is that a patient’s visual acuity on a standard eye chart can remain surprisingly good even while the retina is quietly losing function. That is where electroretinography (ERG) comes in. An ERG records the electrical responses of the retina to light flashes, giving an objective readout of how well the photoreceptors and other retinal cells are working.
Several studies have found that specific ERG measurements track with disease activity. The 30 Hz flicker implicit time, which measures how quickly the retina responds to a flickering light, has shown the most consistent correlation. Abnormalities in this timing and in the amplitudes of other ERG waveforms have been associated with recurrence of inflammation when doctors tried to reduce a patient’s immunosuppressive treatment.13PubMed. Electroretinograms as an indicator of disease activity in birdshot retinochoroidopathy One study of 15 patients found the 30 Hz flicker implicit time was the parameter most strongly correlated with an inability to taper medication safely.14PubMed Central. Visual Electrodiagnostic Testing in Birdshot Chorioretinopathy
In practice, many uveitis specialists order serial ERGs alongside imaging at regular intervals. A worsening ERG can prompt a treatment escalation even when the patient insists they feel fine, and a stable or improving ERG can give confidence that it is safe to carefully step down medication. The timing of 30 Hz flicker, bright scotopic a-wave, and photopic b-wave have been proposed as useful biomarkers for disease activity.15PubMed Central. Electroretinography of disease activity and treatment response in birdshot chorioretinopathy
Treatment Strategy
Birdshot retinopathy requires long-term treatment. Short courses of steroid eye drops alone are almost never sufficient for a disease this deep in the eye, and many patients need systemic therapy for years or indefinitely.
Oral corticosteroids are often the first step to get active inflammation under control quickly. They are effective at damping down inflammation, but the well-known side effects of prolonged steroid use (weight gain, elevated blood sugar, bone thinning, cataracts, glaucoma) make them unsustainable as a standalone approach. The overarching treatment goal is to bring the disease under control and then switch to a corticosteroid-sparing immunosuppressive regimen that keeps inflammation at bay with fewer side effects.
Mycophenolate mofetil is one of the most commonly used steroid-sparing agents. In a long-term follow-up study, it controlled intraocular inflammation in about two-thirds of patients, and 95% of those who had been on systemic steroids were able to taper to a low daily dose.16PubMed. Mycophenolic acid in the treatment of birdshot chorioretinopathy: long-term follow-up Cyclosporine A, sometimes combined with mycophenolate, is another option; the combination has been shown to be well tolerated and associated with sustained inflammation control over a 12-month period.17PubMed. Combined therapy of cyclosporine A and mycophenolate mofetil for the treatment of birdshot retinochoroidopathy: a 12-month follow-up Long-term data on corticosteroid-sparing therapy generally indicate that prompt treatment offers the best chance of preserving retinal function in what would otherwise be a relentlessly progressive disease.18PubMed. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy
Biologic Therapies for Refractory Cases
Some patients do not respond adequately to conventional immunosuppressants or cannot tolerate them. For those refractory cases, biologic agents that target specific immune pathways have become an important option. Infliximab, an anti-TNF-α antibody given by intravenous infusion, controlled inflammation in roughly 82% of patients at six months and 89% at one year in a study where every participant had previously failed conventional therapy.19PubMed. Infliximab treatment of patients with birdshot retinochoroidopathy
Adalimumab, another anti-TNF-α agent delivered by self-injection, has also shown promise for improving visual acuity and allowing doctors to reduce the dose of other immunosuppressants. However, complete remission off all medication was rarely achieved.20RETINA. Adalimumab Therapy for Refractory Birdshot Chorioretinopathy A broader evaluation of anti-TNF-α agents found they were fully effective in about 41% of cases of choroiditis and 50% of cases with venous vasculitis, but their impact on macular edema was disappointing, with most trials showing only partial or no response.21PubMed. Evaluation of Corticosteroids, Immunosuppressants and Biotherapies in Patients with Birdshot Retinochoroidopathy That limitation is worth knowing: macular edema is a common complication that directly threatens central vision, and anti-TNF biologics may not be enough to control it on their own.
Long-Term Visual Outlook
Birdshot retinopathy used to be considered almost inevitably blinding, but the picture has improved considerably with modern immunosuppressive treatment. A ten-year outcome study found that visual acuity remained stable on average across the entire patient population, with 88% of eyes maintaining their acuity and 97% avoiding severe visual loss over that period.22JAMA Ophthalmology. Long-term Clinical and Anatomic Outcome of Birdshot Chorioretinopathy Those are encouraging numbers, though they come from centers experienced in managing the disease aggressively.
Prognostic factors can help predict who will do better or worse. Somewhat counterintuitively, features that look alarming at diagnosis, like vigorous vitreous inflammation, vascular leakage on angiography, and macular edema on OCT, were actually associated with better long-term outcomes in one large French cohort. Patients with macular pigment epithelium atrophy at baseline, by contrast, fared worse.23PubMed. Birdshot Retinochoroidopathy: Prognostic Factors of Long-term Visual Outcome One explanation is that florid inflammation signals active disease that responds to treatment, while early atrophy signals damage already done. Later age of onset was also a positive prognostic sign, which may reflect a less aggressive disease phenotype in older patients.
Complications Beyond Blurred Vision
Even with good acuity on an eye chart, birdshot takes a toll on visual function that standard testing may miss. Loss of contrast sensitivity, color vision, and peripheral visual field are common and can make everyday activities like driving at dusk or reading in poor light genuinely difficult. Quality-of-life research using questionnaires designed specifically for birdshot patients confirmed that they score significantly lower than healthy controls on measures of visual function, daily life, and medication burden. Patients on higher doses of prednisolone also reported worse scores on both the disease-specific and medication-related quality-of-life scales.24Ophthalmology. Development and Validation of Quality-of-Life Questionnaires for Birdshot Chorioretinopathy
Choroidal neovascularization (CNV), where abnormal new blood vessels grow beneath the retina, is another recognized complication. These vessels are fragile and prone to leaking or bleeding, which can cause sudden drops in central vision.25PubMed. Choroidal Neovascularization Associated With Birdshot Chorioretinopathy CNV in birdshot may require anti-VEGF injections, which are a separate treatment from the systemic immunosuppression used for the underlying disease. Cataracts and glaucoma can also develop, sometimes from the disease itself and sometimes as side effects of corticosteroid treatment.
When It Is Not Birdshot
The pale fundus spots that define birdshot have lookalikes. Several other conditions can scatter light-colored lesions across the back of the eye, and distinguishing them matters because the treatments differ. Other “white dot syndromes” such as multifocal choroiditis and acute posterior multifocal placoid pigment epitheliopathy can superficially resemble birdshot, though their lesion patterns, clinical courses, and demographics usually differ once a full workup is done.
More concerning is the possibility of a masquerade syndrome. A case report described a patient whose choroidal lesions mimicked birdshot but who turned out to have findings related to a past low-grade B-cell lymphoma and prior chemotherapy. The key tip-offs were a negative HLA-A29 result and an atypical history. Clinicians are urged to keep masquerade syndromes, including intraocular lymphoma, on the differential when the spots look right but the HLA-A29 test is negative or other features do not fit.26PubMed. Systemic Lymphoma Masquerading as Birdshot Chorioretinopathy This is one reason why HLA-A29 testing is not just an academic exercise but a practical safeguard against missing a very different, potentially life-threatening diagnosis.
Living with a Rare Eye Disease
Beyond the clinical details, the lived experience of birdshot retinopathy involves challenges that do not show up in study endpoints. The disease is rare enough that most general ophthalmologists have little firsthand experience with it, which can make patients feel isolated and uncertain. Finding a uveitis specialist with birdshot expertise often means traveling to a tertiary center. Treatment involves regular blood tests to monitor for side effects of immunosuppressive drugs, periodic imaging and ERG sessions, and the ongoing mental burden of knowing the disease is chronic and may flare at any time.
Patient advocacy groups, particularly active in the UK and the US, have played a meaningful role in connecting patients, accelerating research funding, and pushing for earlier diagnosis. Online communities have also become important, partly because the condition is so rare that few patients will ever meet another person with the same diagnosis in their everyday lives. For someone newly diagnosed, connecting with these networks can be as valuable as finding the right specialist, because the practical wisdom of people who have navigated the medication adjustments, insurance hurdles, and emotional weight of a rare chronic disease is not something a textbook can provide.